CoChat

Targeting TGFβ signal transduction for cancer therapy

Open access
Liu, Sijia, Ren, Jiang, ten Dijke, Peter · 2021 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 329 of the 330 references it cites were found in a registry or an index.

Abstract

Transforming growth factor-β (TGFβ) family members are structurally and functionally related cytokines that have diverse effects on the regulation of cell fate during embryonic development and in the maintenance of adult tissue homeostasis. Dysregulation of TGFβ family signaling can lead to a plethora of developmental disorders and diseases, including cancer, immune dysfunction, and fibrosis. In this review, we focus on TGFβ, a well-characterized family member that has a dichotomous role in cancer progression, acting in early stages as a tumor suppressor and in late stages as a tumor promoter. The functions of TGFβ are not limited to the regulation of proliferation, differentiation, apoptosis, epithelial-mesenchymal transition, and metastasis of cancer cells. Recent reports have related TGFβ to effects on cells that are present in the tumor microenvironment through the stimulation of extracellular matrix deposition, promotion of angiogenesis, and suppression of the anti-tumor immune reaction. The pro-oncogenic roles of TGFβ have attracted considerable attention because their intervention provides a therapeutic approach for cancer patients. However, the critical function of TGFβ in maintaining tissue homeostasis makes targeting TGFβ a challenge. Here, we review the pleiotropic functions of TGFβ in cancer initiation and progression, summarize the recent clinical advancements regarding TGFβ signaling interventions for cancer treatment, and discuss the remaining challenges and opportunities related to targeting this pathway. We provide a perspective on synergistic therapies that combine anti-TGFβ therapy with cytotoxic chemotherapy, targeted therapy, radiotherapy, or immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-00436-9

Cites

329 of 329 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Biphasic functions of TGFβ during tumor progression. TGFβ acts as a tumor suppressor in the initial stage of tumor progression by inducing cell cycle arrest and apoptosis of normal and pre-malignant epithelial cells. Upon activation of oncogenes and/or inactivation of tumor suppressor genes, tumor cells become insensitive to the TGFβ-induced cytostatic effects and undergo uncontrolled proliferation. TGFβ produced by tumor cells, fibroblasts, immune, and endothelial cells in the tumor microenvironment (TME) can trigger cancer cells to undergo an epithelial-to-mesenchymal transition (EMT). Thereby, late-stage cancer cells acquire the ability to escape from the primary niche, intravasate into the circulation, extravasate and localize to distant sites, and progress to form secondary tumors. Reciprocal TGFβ signaling between cancer cells and the TME contributes to cancer progression by activating cancer-associated fibroblasts (CAFs), stimulating angiogenesis, promoting protumor cytokine secretion, increasing extracellular matrix deposition, and evading an immune attack. In the metastatic sites, the mesenchymal tumor cells can undergo a mesenchymal-to-epithelial transition. Thus, thereby change back into an epithelial phenotype, which enables rapid outgrowth
Fig. 1 Biphasic functions of TGFβ during tumor progression. TGFβ acts as a tumor suppressor in the initial stage of tumor progression by inducing cell cycle arrest and apoptosis of normal and pre-malignant epithelial cells. Upon activation of oncogenes and/or inactivation of tumor suppressor genes, tumor cells become insensitive to the TGFβ-induced cytostatic effects and undergo uncontrolled proliferation. TGFβ produced by tumor cells, fibroblasts, immune, and endothelial cells in the tumor microenvironment (TME) can trigger cancer cells to undergo an epithelial-to-mesenchymal transition (EMT). Thereby, late-stage cancer cells acquire the ability to escape from the primary niche, intravasate into the circulation, extravasate and localize to distant sites, and progress to form secondary tumors. Reciprocal TGFβ signaling between cancer cells and the TME contributes to cancer progression by activating cancer-associated fibroblasts (CAFs), stimulating angiogenesis, promoting protumor cytokine secretion, increasing extracellular matrix deposition, and evading an immune attack. In the metastatic sites, the mesenchymal tumor cells can undergo a mesenchymal-to-epithelial transition. Thus, thereby change back into an epithelial phenotype, which enables rapid outgrowthCC BY · PubMed Central
Fig. 2 A schematic representation of the activation of latent TGFβ. The pro-TGFβ precursor is synthesized in the rough endoplasmic reticulum. It consists of an N-terminal signal peptide, latency-associated peptide (LAP), and a mature C-terminal TGFβ fragment. After cleavage by the convertase furin in the Golgi complex, the LAP dimer binds to mature TGFβ noncovalently, preventing its binding to cell surface receptors, and forms the small latent complex (SLC). There are three major mechanisms for activation of latent TGFβ. a Proteases (e.g., cathepsin, plasmin, matrix metalloproteinase 9/14 (MMP9/14)) in the extracellular matrix (ECM) cleave LAP and release active TGFβ. Also, thrombospondin (TSP) can induce activation by direct binding to LAP. b SLC is anchored to the ECM proteins (e.g., fibronectin and fibrillin) via latent TGFβ-binding protein (LTBP) and forms the so-called large latent complex (LLC). Active TGFβ can be released by cell contraction upon the interaction between LAP and integrins. c SLC binds to glycoprotein A repetition predominant protein (GARP) on the cell surface and can also mediate the release of active TGFβ upon interaction with integrins
Fig. 2 A schematic representation of the activation of latent TGFβ. The pro-TGFβ precursor is synthesized in the rough endoplasmic reticulum. It consists of an N-terminal signal peptide, latency-associated peptide (LAP), and a mature C-terminal TGFβ fragment. After cleavage by the convertase furin in the Golgi complex, the LAP dimer binds to mature TGFβ noncovalently, preventing its binding to cell surface receptors, and forms the small latent complex (SLC). There are three major mechanisms for activation of latent TGFβ. a Proteases (e.g., cathepsin, plasmin, matrix metalloproteinase 9/14 (MMP9/14)) in the extracellular matrix (ECM) cleave LAP and release active TGFβ. Also, thrombospondin (TSP) can induce activation by direct binding to LAP. b SLC is anchored to the ECM proteins (e.g., fibronectin and fibrillin) via latent TGFβ-binding protein (LTBP) and forms the so-called large latent complex (LLC). Active TGFβ can be released by cell contraction upon the interaction between LAP and integrins. c SLC binds to glycoprotein A repetition predominant protein (GARP) on the cell surface and can also mediate the release of active TGFβ upon interaction with integrinsCC BY · PubMed Central
Fig. 3 Schematic of the TGFβ-induced canonical SMAD and noncanonical signaling pathways. a TβRIII presents TGFβ to TβRII. Thereafter, ligand occupied TβRII recruits and phosphorylates TβRI to trigger intracellular TGFβ signaling pathways. In the canonical pathway, activated TβRI phosphorylates SMAD2/3 and stimulates the formation of heteromeric complexes with SMAD4. These complexes are translocated into the nucleus and regulate target gene expression. One of the TGFβ/SMAD-induced target genes is SMAD7, of which the gene product participates in a negative feedback loop to regulate the duration and intensity of TGFβ signaling by recruiting E3 ubiquitin ligase SMURF to TβRI. b TGFβ pathway target genes relevant for tumor suppression are listed in green, and the target genes that encode proteins involved in the tumor promotion are listed in red. c TGFβ can also activate many noncanonical pathways, including RHO, JNK, p38, NF-κB, AKT, and ERK signaling components
Fig. 3 Schematic of the TGFβ-induced canonical SMAD and noncanonical signaling pathways. a TβRIII presents TGFβ to TβRII. Thereafter, ligand occupied TβRII recruits and phosphorylates TβRI to trigger intracellular TGFβ signaling pathways. In the canonical pathway, activated TβRI phosphorylates SMAD2/3 and stimulates the formation of heteromeric complexes with SMAD4. These complexes are translocated into the nucleus and regulate target gene expression. One of the TGFβ/SMAD-induced target genes is SMAD7, of which the gene product participates in a negative feedback loop to regulate the duration and intensity of TGFβ signaling by recruiting E3 ubiquitin ligase SMURF to TβRI. b TGFβ pathway target genes relevant for tumor suppression are listed in green, and the target genes that encode proteins involved in the tumor promotion are listed in red. c TGFβ can also activate many noncanonical pathways, including RHO, JNK, p38, NF-κB, AKT, and ERK signaling componentsCC BY · PubMed Central
Fig. 4 The functions of TGFβ upon the epithelial–mesenchymal transition (EMT). a Schematic of TGFβ mediation of the EMT process. b TGFβ promotes the EMT in non-transformed NAMRU mouse mammary gland (NMuMG) epithelial cells, as visualized by immunofluorescent staining of cells with anti-E-cadherin antibody (red) and phalloidin (green) to measure filamentous actin expression in the absence and after treatment with 5 ng/ml TGFβ3 for 48 h. The typical morphological change from epithelial- to fibroblast-like cells, decreased E-cadherin, and accumulated striated fibers are observed in the NMuMG cells upon TGFβ stimulation. c TGFβ promotes the migration of MDA-MB-231 human breast cancer cells, as determined via real-time imaging of a wound-healing scratch assay. Left, graph showing the time-lapse relative migration rate; right, images of the cells taken when the initial scratch was made (0 h) and after 24 and 48 h in the absence or presence of 5 ng/ml TGFβ3
Fig. 4 The functions of TGFβ upon the epithelial–mesenchymal transition (EMT). a Schematic of TGFβ mediation of the EMT process. b TGFβ promotes the EMT in non-transformed NAMRU mouse mammary gland (NMuMG) epithelial cells, as visualized by immunofluorescent staining of cells with anti-E-cadherin antibody (red) and phalloidin (green) to measure filamentous actin expression in the absence and after treatment with 5 ng/ml TGFβ3 for 48 h. The typical morphological change from epithelial- to fibroblast-like cells, decreased E-cadherin, and accumulated striated fibers are observed in the NMuMG cells upon TGFβ stimulation. c TGFβ promotes the migration of MDA-MB-231 human breast cancer cells, as determined via real-time imaging of a wound-healing scratch assay. Left, graph showing the time-lapse relative migration rate; right, images of the cells taken when the initial scratch was made (0 h) and after 24 and 48 h in the absence or presence of 5 ng/ml TGFβ3CC BY · PubMed Central
Fig. 5 Functions of TGFβ in the tumor microenvironment (TME). a TGFβ can activate/differentiate resident fibroblasts, mesenchymal stem cells, epithelial tumor cells, adipose tissue-derived stem cells, and endothelial cells into cancer-associated fibroblasts (CAFs) in the TME. b TGFβ promotes angiogenesis in the TME by acting directly and indirectly on endothelial cells stimulating their proliferation, migration, and sprouting. c TGFβ crucially suppresses the immune system by regulating the functions of immune cell populations in the TME. The specific actions of TGFβ are indicated in the boxes next to the different immune cells that are depicted
Fig. 5 Functions of TGFβ in the tumor microenvironment (TME). a TGFβ can activate/differentiate resident fibroblasts, mesenchymal stem cells, epithelial tumor cells, adipose tissue-derived stem cells, and endothelial cells into cancer-associated fibroblasts (CAFs) in the TME. b TGFβ promotes angiogenesis in the TME by acting directly and indirectly on endothelial cells stimulating their proliferation, migration, and sprouting. c TGFβ crucially suppresses the immune system by regulating the functions of immune cell populations in the TME. The specific actions of TGFβ are indicated in the boxes next to the different immune cells that are depictedCC BY · PubMed Central
Fig. 6 Schematic of strategies utilized in (pre)clinical trials targeting TGFβ signal transduction for cancer therapy. Various pharmacological interventions are grouped into the targeting of different TGFβ signaling components, that is, TGFβ mRNA, GARP/integrins that are involved in activation of latent TGFβ, and ligands that interact with TGFβ receptors and TβRI kinase activity. The promising new targeting molecules that have been studied in pre-clinical models are highlighted in red color. Different strategies for targeting TGFβ signaling, including antisense oligonucleotide (AON), neutralizing antibody (antibody), cyclic RGD pentapeptide, TGFβ ligand trap (trap), and small-molecule kinase inhibitor (SKI) are indicated. The immune regulatory targets (CTLA4/PD-L1/CD4) of the bispecific molecules that sequester TGFβ with a TβRII extracellular domain containing trap are highlighted in the orange circle
Fig. 6 Schematic of strategies utilized in (pre)clinical trials targeting TGFβ signal transduction for cancer therapy. Various pharmacological interventions are grouped into the targeting of different TGFβ signaling components, that is, TGFβ mRNA, GARP/integrins that are involved in activation of latent TGFβ, and ligands that interact with TGFβ receptors and TβRI kinase activity. The promising new targeting molecules that have been studied in pre-clinical models are highlighted in red color. Different strategies for targeting TGFβ signaling, including antisense oligonucleotide (AON), neutralizing antibody (antibody), cyclic RGD pentapeptide, TGFβ ligand trap (trap), and small-molecule kinase inhibitor (SKI) are indicated. The immune regulatory targets (CTLA4/PD-L1/CD4) of the bispecific molecules that sequester TGFβ with a TβRII extracellular domain containing trap are highlighted in the orange circleCC BY · PubMed Central
Fig. 7 Sketch of synergistic combination therapies. a Chemo/radio/targeted therapy alone inhibits the growth of epithelial-like tumor cells, and in combination with anti-TGFβ therapy, invasive escape and resistance to these therapies are attenuated, and metastasis of mesenchymal tumor cells is restrained. b Activated CAFs mediated by high TGFβ activity suppresses immunotherapy efficacy by blocking T cell infiltration into tumors and inducing T cell dysfunction. In combination with anti-TGFβ therapy; however, T cell exclusion is inhibited, and the antitumor efficacy of the immunotherapy is improved
Fig. 7 Sketch of synergistic combination therapies. a Chemo/radio/targeted therapy alone inhibits the growth of epithelial-like tumor cells, and in combination with anti-TGFβ therapy, invasive escape and resistance to these therapies are attenuated, and metastasis of mesenchymal tumor cells is restrained. b Activated CAFs mediated by high TGFβ activity suppresses immunotherapy efficacy by blocking T cell infiltration into tumors and inducing T cell dysfunction. In combination with anti-TGFβ therapy; however, T cell exclusion is inhibited, and the antitumor efficacy of the immunotherapy is improvedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–329 of 329

Research works printed but not linked: 3

  1. Derynck, R., Muthusamy, B. P. & Saeteurn, K. Y. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 31, 56–66 (2014). · DOI · Paper page
  2. Kim, H. S. et al. A phase I study of TGF-β inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis). J. Clin. Oncol. 38, e11557 (2020). · DOI
  3. Derynck, R. & Budi, E. H. J. Ss Specificity, versatility, and control of TGF-β family signaling. Sci. Signal 12, eaav5183 (2019). · DOI · Paper page

Cited by

See all 426

Metadata

Authors
Liu, S., Ren, J., & ten Dijke, P.
Affiliations
Leiden University Medical Center (NL)
Venue
Signal Transduction and Targeted Therapy
Published
2021-01-08
Volume
6
Issue
1
Pages
8-8
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3119664087
Cited by
413
References
330
Citations by year
2026: 56 · 2025: 95 · 2024: 89 · 2023: 74 · 2022: 58 · 2021: 41
FWCI
7.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Cancer Genomics Centre
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
TGF-beta signaling, cancer therapy, tumor suppressor, tumor promoters, epithelial-mesenchymal transition, metastasis, tumor microenvironment, extracellular matrix deposition, angiogenesis, combination therapy, chemotherapy, targeted therapy, radiotherapy, immunotherapy
MeSH terms
Humans, Neoplasm Proteins, Neoplasms, Signal Transduction, Transforming Growth Factor beta, Epithelial-Mesenchymal Transition, Tumor Microenvironment, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.